Efficacy of TPI ASM8 During a 14-Day Allergen Challenge

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled, 3-way crossover trial to evaluate the efficacy and safety of two different doses of inhaled TPI ASM8 administered daily for 14 days for the treatment of allergic asthma and allergen-induced asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmaxis

Criteria

Inclusion Criteria:

• Mild asthma, male and female aged 18-55 y.old

• Steroid-naive, non-smoker

• Dual responders

Exclusion Criteria:

• Any chronic disease(unstable)

• Immunosuppressed, recent or ongoing steroid intake

• Methacholine PC 20 > 16 mg/mL